Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | COPS5 | Q92905 | 5/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1548680 | 0.81 | COPS5 (0.40) | L3MBTL1COPS5HCAR2USP2NPC1 | |
| SCHEMBL3838148 | 0.77 | L3MBTL1 (0.43) | L3MBTL1COPS5HCAR2NPC1RAB9A | |
| SCHEMBL22774382 | 0.77 | L3MBTL1 (0.40) | L3MBTL1COPS5HCAR2NPC1RAB9A | |
| SCHEMBL11183274 | 0.76 | L3MBTL1 (0.39) | L3MBTL1COPS5HCAR2NPC1RAB9A | |
| SCHEMBL755522 | 0.76 | ALDH1A1 (0.44) | L3MBTL1COPS5HCAR2NPC1RAB9A | |
| Bromide SCHEMBL7136559 | 0.74 | COPS5 (0.52) | L3MBTL1COPS5ALDH1A1 | |
| SCHEMBL1548237 | 0.73 | L3MBTL1 (0.38) | L3MBTL1COPS5HCAR2NPC1RAB9A | |
| SCHEMBL1548276 | 0.73 | L3MBTL1 (0.38) | L3MBTL1COPS5HCAR2NPC1RAB9A | |
| SCHEMBL1548239 | 0.73 | L3MBTL1 (0.38) | L3MBTL1COPS5HCAR2NPC1RAB9A | |
| SCHEMBL28135175 | 0.71 | L3MBTL1 (0.36) | L3MBTL1COPS5HCAR2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2292639-B1 | Tubulisine derivatives as anticancer drugs | KEMOTECH S R L (IT) | 2014-09-03 | — | — | EP | disclosed |
| US-8580820-B2 | Tubulysin compounds with high cytotoxicity, pharmaceutical compositions thereof, and method of use thereof | KEMTECH S.R.L. (IT) | 2013-11-12 | — | — | US | disclosed |
| US-20110200581-A1 | PHARMACEUTICAL COMPOSITIONS | KEMOTECH S.r.I (IT) | 2011-08-18 | — | — | US | disclosed |
| EP-2292639-A1 | Tubulisine derivatives as anticancer drugs | Kemotech S.r.l. (IT) | 2011-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200581-A1 | PHARMACEUTICAL COMPOSITIONS | NR1H3, NR1H2, CCR8 | L3MBTL1 3449/4885COPS5 836/4885HCAR2 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.